- Home
- VINO vs PBM Comparison
VINO vs PBM Comparison
Compare VINO & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINO
- PBM
- Stock Information
- Founded
- VINO 1999
- PBM 1994
- Country
- VINO United States
- PBM Canada
- Employees
- VINO N/A
- PBM N/A
- Industry
- VINO Real Estate
- PBM
- Sector
- VINO Finance
- PBM
- Exchange
- VINO Nasdaq
- PBM NYSE
- Market Cap
- VINO 4.4M
- PBM 4.0M
- IPO Year
- VINO N/A
- PBM N/A
- Fundamental
- Price
- VINO $4.36
- PBM $0.10
- Analyst Decision
- VINO
- PBM
- Analyst Count
- VINO 0
- PBM 0
- Target Price
- VINO N/A
- PBM N/A
- AVG Volume (30 Days)
- VINO 17.6K
- PBM 6.2M
- Earning Date
- VINO 11-15-2024
- PBM 11-02-2024
- Dividend Yield
- VINO N/A
- PBM N/A
- EPS Growth
- VINO N/A
- PBM N/A
- EPS
- VINO N/A
- PBM N/A
- Revenue
- VINO $2,006,876.00
- PBM N/A
- Revenue This Year
- VINO N/A
- PBM N/A
- Revenue Next Year
- VINO N/A
- PBM N/A
- P/E Ratio
- VINO N/A
- PBM N/A
- Revenue Growth
- VINO 1.79
- PBM N/A
- 52 Week Low
- VINO $3.89
- PBM $0.09
- 52 Week High
- VINO $13.50
- PBM $14.55
- Technical
- Relative Strength Index (RSI)
- VINO 37.53
- PBM 24.23
- Support Level
- VINO $4.00
- PBM $0.11
- Resistance Level
- VINO $5.81
- PBM $0.14
- Average True Range (ATR)
- VINO 0.54
- PBM 0.01
- MACD
- VINO -0.01
- PBM 0.01
- Stochastic Oscillator
- VINO 19.94
- PBM 21.88
About VINO Gaucho Group Holdings Inc.
Gaucho Group Holdings Inc develops and operates real estate projects in Argentina. It operates a hotel, golf and tennis resort, vineyard and producing winery in addition to developing residential lots located near the resort. The company operates in three segments which are the business of real estate development and manufacture; the sale of high-end fashion and accessories through an e-commerce platform; corporate operations. It derives majority of its revenue from the Real Estate Development segment.
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.